Strategies for herpes zoster vaccination of immunocompromised patients

Journal of Infectious Diseases

Volumn 197, Issue SUPPL. 2, 2008, Pages

  Cohen, Jeffrey I ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIVE VACCINE; MEASLES MUMPS RUBELLA VACCINE; PLACEBO; PREDNISONE; SUBUNIT VACCINE; VARICELLA ZOSTER VACCINE; VIRUS PROTEIN;

BONE MARROW TRANSPLANTATION; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL TRIAL; CONFERENCE PAPER; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; HERPES ZOSTER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOCOMPROMISED PATIENT; INJECTION SITE REACTION; PAIN; PRIORITY JOURNAL; SKIN INDURATION; TREATMENT CONTRAINDICATION; VACCINATION; VARICELLA ZOSTER VIRUS; VIRUS REPLICATION;

AGED; CHICKENPOX VACCINE; HERPES ZOSTER; HERPES ZOSTER VACCINE; HERPESVIRUS 3, HUMAN; HUMANS; IMMUNOCOMPROMISED HOST; VACCINATION;

EID: 42549171504     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/522129     Document Type: Conference Paper

References (25)

1. Kost RG, Straus SE. Postherpetic neuralgia - pathogenesis, treatment, and prevention. N Engl J Med 1996; 335:32-42.
2. Oxman MN. Clinical manifestations of herpes zoster. In: Arvin AM, Gershon AA, eds. Varicella-zoster virus. Cambridge: Cambridge University Press, 2000:246-75.
3. LaRussa P, Steinberg S, Gershon AA. Varicella vaccine for immunocompromised children: results of collaborative studies in the United States and Canada. J Infect Dis 1996; 174(Suppl 3):S320-3.
4. Levin MJ, Gershon AA, Weinberg A, et al. Immunization of HIV-infected children with varicella vaccine. J Pediatr 2001; 139:305-10.
5. Armenian SH, Han JY, Dunaway TM, Church JA. Safety and immunogenicity of live varicella virus vaccine in children with human immunodeficiency virus type 1. Pediatr Infect Dis J 2006; 25:368-70.
6. Weinberg A, Horslen SP, Kaufman SS, et al. Safety and immunogenicity of varicella-zoster virus vaccine in pediatric liver and intestinal transplant recipients. Am J Transplant 2006; 6:565-8.
7. Khan S, Ehrlichman J, Rand EB. Live virus immunization after orthotopic liver transplantation. Pediatr Transplant 2006; 10:78-82.
8. Marin M, Güris D, Chaves SS, Schmid S, Seward JF, Advisory Com mittee on Immunization Practices, Centers for Disease Control and Prevention. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007; 56(RR-4):1-40.
9. Oxman M, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia. N Engl J Med 2005; 352:2271-84.
10. Levin MJ, Murray M, Zerbe GO, White CJ, Hayward AR. Immune response of elderly persons 4 years after receiving a live attenuated varicella vaccine. J Infect Dis 1994; 170:522-6.
11. Kuter BJ, Ngai A, Patterson CM, et al. Safety, tolerability, and immunogenicity of two regimens of Oka/Merck varicella vaccine (Varivax) in healthy adolescents and adults. Vaccine 1995; 13:967-72.
12. Gershon AA, Steinberg SP. Persistence of immunity to varicella in children with leukemia immunized with live attenuated varicella vaccine. N Engl J Med 1989; 320:892-7.
13. Arvin AM. Varicella zoster virus. In: Knipe DM, Howley PM, et al. Fields virology. Philadelphia: Lipincott-Williams & Wilkins, 2001: 2731-67.
14. + T cells. J Infect Dis 2006; 194:247-55.
15. Levin MJ, Ellison MC, Zerbe GO, et al. Comparison of a live attenuated and an inactivated varicella vaccine to boost the varicella-specific immune response in seropositive people 55 years of age and older. Vaccine 2000; 18:2915-20.
16. Redman RL, Nader S, Zerboni L, et al. Early reconstitution of immunity and decreased severity of herpes zoster in bone marrow transplant recipients immunized with inactivated varicella vaccine. J Infect Dis 1997; 176:578-85.
17. Hata A, Asanuma H, Rinki M, et al. Use of an inactivated varicella vaccine in recipient of hematopoietic-cell transplants. N Engl J Med 2002; 347:26-34.
18. Levin MJ. Use of varicella-zoster virus vaccines to prevent herpes zoster in older individuals. Arch Virol Suppl 2001; 17:151-60.
19. Takahashi M, Kamiya H, Asano Y, et al. Immunization of the elderly to boost immunity against varicella-zoster virus (VZV) as assessed by VZV skin test reaction. Arch Virol Suppl 2001; 17:161-72.
20. Sperber SJ, Smith BV, Hayden FG. Serologic response and reactogenicity to booster immunization of healthy seropositive adults with live or inactivated varicella vaccine. Antiviral Res 1992; 17:213-22.
21. Hayward AR, Buda K, Levin MJ. Immune response to secondary immunization with live or inactivated VZV vaccine in elderly adults. Viral Immunol 1994; 7:31-6.
22. Hayward AR, Buda K, Jones M, et al. VZV specific cytotoxicity following secondary immunization with live or killed vaccine. Viral Immunol 1996; 9:241-5.
23. Mo C, Suen J, Sommer M, Arvin A. Characterization of varicella-zoster virus glycoprotein K (open reading frame 5) and its role in virus growth. J Virol 1999; 73:4197-207.
24. Cohen JI, Krogmann T, Ross JP, Pesnicak LP, Prikhod'ko EA. The varicella-zoster virus ORF4 latency associated protein is important for establishment of latency. J Virol 2005; 79:6969-75.
25. Xia D, Srinivas S, Sato H, Pesnicak L, Straus SE, Cohen JI. Varicella-zoster virus ORF21, which is expressed during latency, is essential for virus replication but dispensable for establishment of latency. J Virol 2003; 77:1211-8.